Tennessee § 56-7-3712 Changing prior authorization requirements

Tennessee Statutes

§ 56-7-3712 — Changing prior authorization requirements

Tennessee § 56-7-3712

Title56

This text of Tennessee § 56-7-3712 (Changing prior authorization requirements) is published on Counsel Stack Legal Research, covering Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tenn. Code Ann. § 56-7-3712 (2026).

Text

(a)A utilization review organization shall provide notice to healthcare providers in its network of each new prior authorization requirement, or restriction or amendment to an existing prior authorization requirement, at least sixty (60) days prior to the effective date of the change.

(b)A utilization review organization shall provide notice to healthcare providers in its network of each new prior authorization requirement, or restriction or amendment to an existing prior authorization requirement, for a prescription drug at least forty-five (45) days prior to the effective date of the change unless any of the following apply:

(1)The United States food and drug administration has:

(A)Issued a statement that calls into question the clinical safety of the drug;

(B)Required the manufactu

Free access — add to your briefcase to read the full text and ask questions with AI

(a) A utilization review organization shall provide notice to healthcare providers in its network of each new prior authorization requirement, or restriction or amendment to an existing prior authorization requirement, at least sixty (60) days prior to the effective date of the change. (b) A utilization review organization shall provide notice to healthcare providers in its network of each new prior authorization requirement, or restriction or amendment to an existing prior authorization requirement, for a prescription drug at least forty-five (45) days prior to the effective date of the change unless any of the following apply: (1) The United States food and drug administration has: (A) Issued a statement that calls into question the clinical safety of the drug; (B) Required the manufacturers to conduct post-market safety studies and clinical trials after the approval of the drug; (C) Issued any drug safety-related labeling changes; or (D) Required the manufacturers to implement special risk management programs; (2) The drug receives a new approval from the United States food and drug administration and has become available; or (3) The United States food and drug administration has approved expanded use of the drug. (c) Notice required by this section must be distributed through: (1) The utilization review organization's website or the healthcare provider's portal; and (2) Written communication sent to a dedicated email address and regular mailing address for the healthcare provider or as stipulated in the contract between the healthcare provider and the utilization review organization. The healthcare provider may be required to submit a dedicated email address and regular mailing address to receive the notices required by this subsection (c).